Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies

Author： Dal Piaz V.   Giovannoni M.P.  

Publisher： Elsevier

ISSN： 0223-5234

Source： European Journal of Medicinal Chemistry, Vol.35, Iss.5, 2000-05, pp. : 463-480

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase 4 inhibitors for the treatment of asthma

By Karlsson J-A.   Aldous D.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 9, 1997-09 ,pp. : 989-1003

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and COPD

By  

Current Medicinal Chemistry, Vol. 13, Iss. 27, 2006-11 ,pp. : 3253-3262

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions

By  

Current Medicinal Chemistry, Vol. 23, Iss. 2, 2016-01 ,pp. : 129-141

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease

By Spina D.  

Drugs, Vol. 63, Iss. 23, 2003-01 ,pp. : 2575-2594

Adis International

Access to resources Recommend Favorite

Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?

By Giembycz M.A.  

Drugs, Vol. 59, Iss. 2, 2000-02 ,pp. : 193-212

Adis International

Access to resources Recommend Favorite